Effect of Modified Xuanbai Chengqi Decoction on Immune Imbalance in Children with Mycoplasma Pneumoniae Pneumonia:A Randomized Controlled Trial
Objective To observe the effects of modified Xuanbai Chengqi Decoction(XBCQD)on the expression levels of soluble B7 cognate body 3(sB7-H3)and associated cytokines in the serum of children suffering from mycoplasma pneumoniae pneumonia(MPP,Fei-heat and organ-sthenia syndrome),and to explore its underlying mechanisms.Methods Eighty-eight children with MPP were recruited and randomly assigned to the observation group(46 cases)and the control group(42 cases).Both groups received standard treatments including Azithromycin for anti-infection,and medications for cough relief and phlegm resolution.The observation group additionally received the modified XBCQD orally for three days.The clinical efficacy and serum levels of sB7-H3,C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),interleukin-2,4,6,10,17(IL-2,4,6,10,17),and interferon gamma(IFN-γ)were measured and compared before and after the treatment.Results Totally 86 patients were finally included in analysis,45 patients in the observation group and 43 patients in the control group.The total effectiveness rate in the observation group was 95.6％(42/45),which was significantly higher than the 80.5％(33/41)in the control group(x2=4.74,P=0.043).Compared with baseline,the sB7-H3,CRP,ESR,and IL-4,6,10,17 levels decreased(P＜0.05),the IL-2 and IFN-γ levels increased in two groups after treatment(P＜0.05).After treatment compared with the control group,the IL-2 and IFN-γ levels decreased,levels of sB7-H3,CRP,ESR,and IL-4,6,10,17 increased in the observation group(P＜0.05).Conclusion Modified XBCQD can modulate immune imbalance in children with MPP by affecting the expression of sB7-H3 and related inflammatory cytokines,thereby improving clinical symptoms and signs during the acute phase.
国家科技期刊平台
NSTL
万方数据
